Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 47, Issue 10, Pages 2405-2408Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm0304515
Keywords
-
Categories
Ask authors/readers for more resources
The nature and the size of the benzylic substituent are shown to be the key to controlling receptor selectivity (CCR5 vs M1, M2) and potency in the title compounds. Optimization of the lead benzylic methyl compound 3 led to the methoxymethyl analogue 30, which had excellent receptor selectivity and oral bioavailability in rats and monkeys. Compound 30 (Sch-417690/Sch-D), a potent inhibitor of HIV-1 entry into target cells, is currently in clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available